To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.
Promotion in emerging markets offers several very important benefits to pharmaceutical companies:
Jay Carter
However, it is a flawed assumption to believe that growing a marketing presence in emerging markets automatically requires a global agency network.
Savvy global marketers should consider other options carefully. Here are four reasons why:
1. If the market you are entering is truly emerging, there is likely to be uneven quality among local agencies. It may sound appealing to hear a network executive claim uniform excellence. However, if there is even a 75 percent chance that the network you contract with has the best agency for a client's brand in a specific market (a spectacularly generous assumption), then the chances that six countries will all have the best agency with a single network is a whopping 18 percent. Simple statistics dictate that a global leader allow—even encourage—each affiliate to choose the agency that is the best fit locally.
2. As you build local affiliates, hire and develop independent leaders for them. This is an imperative for all of the organizations I work with on a daily basis. Taking away the ability of the affiliate general managers to select their own agencies reduces their ability to truly adapt to local needs.
3. The cost savings often cited by networks are based upon reducing the cost of creating six different campaigns, and not upon reducing local affiliate labor costs; each affiliate will still need to execute tactics locally.
4. For all these reasons, AbelsonTaylor advocates a simple brand book process: the pharmaceutical company's global marketing organization (often in partnership with the US affiliate, due to its dominant size) collaborates on the necessary insight work and brand development to create a global brand.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.